You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 7,682,628


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,682,628
Title:Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
Abstract: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present invention for treating sleep disorders such as insomnia are also provided.
Inventor(s): Singh; Nikhilesh N. (Mill Valley, CA)
Assignee: Transcept Pharmaceuticals, Inc. (Pt. Richmond, CA)
Application Number:11/833,323
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,682,628
Patent Claims: 1. A method for treating insomnia, comprising the steps of: administering a solid pharmaceutical composition comprising zolpidem or a pharmaceutically acceptable salt thereof to a subject prone to insomnia, the pharmaceutical composition further comprising a buffer, wherein the buffer raises the pH of saliva to a pH of about 7.8 or greater, wherein zolpidem is absorbed across a permeable membrane of the subject's oral mucosa, and wherein at least 75% of the solid pharmaceutical composition dissolves within about 10 minutes or less within an oral cavity following administration.

2. The method of claim 1, wherein the solid pharmaceutical composition further comprises a binder and a disintegrating agent.

3. The method of claim 1, wherein the solid pharmaceutical composition dissolves within about 1-3 minutes within the oral cavity of the subject following administration.

4. The method of claim 1, wherein the solid pharmaceutical composition dissolves within about 2-3 minutes within the subject's oral cavity following administration.

5. The method of claim 1, wherein the solid pharmaceutical composition is administered sublingually.

6. The method of claim 1, wherein the oral mucosa is selected from the group consisting of sublingual mucosa, buccal mucosa, gingival mucosa, palatal mucosa, and lining of the lips.

7. The method of claim 1, wherein a mean peak plasma concentration of zolpidem between about 20 to about 100 ng/mL is produced within about 30 minutes.

8. The method of claim 1, wherein a therapeutically effective amount of zolpidem enters the bloodstream within about 30 minutes.

9. The method of claim 1, wherein the buffer comprises a carbonate buffer and a bicarbonate buffer.

10. The method of claim 9, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:10.

11. The method of claim 1, wherein the solid pharmaceutical composition is a lozenge.

12. The method of claim 1, wherein the solid pharmaceutical composition is a tablet.

13. The method of claim 9, wherein the carbonate buffer and bicarbonate buffer are present in a carbonate:bicarbonate weight ratio of about 1:1 to about 1:5.

14. The method of claim 1, wherein an average plasma concentration is from about 20 to about 300 ng/ml.

15. The method of claim 1, wherein the zolpidem or pharmaceutically acceptable salt is zolpidem tartrate.

16. The method of claim 1, wherein the zolpidem or pharmaceutically acceptable salt thereof is in an amount from about 1 mg to about 5 mg.

17. The method of claim 1, wherein the zolpidem or pharmaceutically acceptable salt thereof is in an amount from about 2 mg to about 5 mg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.